Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD23, also known as FcεRII or CLEC4J, is a multifunctional cell surface receptor with key roles in immunoregulation, particularly in the context of IgE-mediated immune responses and allergy. It is a type II transmembrane glycoprotein and a member of the C-type lectin family. CD23 exists in two main isoforms, CD23a and CD23b, with differing expression patterns. It binds IgE with low affinity and also interacts with CD21, MHC II molecules, and certain integrins. CD23 plays a central role in regulating serum IgE levels and has been investigated as a therapeutic target for allergy and asthma interventions.
Antibodies targeting CD23 aim to reduce pathological allergic responses by modulating antibody production and presentation pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cluster of Differentiation 23 (CD23).